Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 7/20 | 0.40 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31674301 | 1.00 | TNIK (0.40) | TNIKKMOPTGS2PRMT5WDR77 | |
| SCHEMBL32683889 | 0.83 | PTGS2 (0.47) | TNIKPTGS2MIFNPC1 | |
| SCHEMBL32683274 | 0.83 | PTGS2 (0.47) | TNIKPTGS2MIF | |
| SCHEMBL32683548 | 0.83 | MIF (0.47) | TNIKKMOMIFNPC1 | |
| SCHEMBL31379284 | 0.70 | TNIK (0.42) | TNIKPTGS2MIFNPC1 | |
| SCHEMBL15822463 | 0.68 | MIF (0.42) | MIFNPC1 | |
| SCHEMBL32683262 | 0.68 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL32683871 | 0.68 | PRMT5 (0.37) | PRMT5WDR77 | |
| SCHEMBL34475640 | 0.67 | POLB (0.52) | TNIKMIFNPC1 | |
| SCHEMBL14931625 | 0.66 | ALDH1A1 (0.47) | NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743175-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | ACONCAGUA BIO, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. | 2025-08-14 | — | — | US | disclosed |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2025015269-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486269-B2 | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity | IAPP, GIPR, SCTR | TNIK 2724/4885KMO 4766/4885PTGS2 2137/4885 |
| US-20260042760-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | NPY1R, CALCRL, SCTR | TNIK 4350/4885KMO 4266/4885PTGS2 3409/4885 |
| US-20250257067-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | IAPP, GIPR, SCTR | TNIK 2724/4885KMO 4766/4885PTGS2 2137/4885 |
| US-20250051355-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | TNIK 3209/4885KMO 4712/4885PTGS2 2829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.